Progesterone (P4) and the synthetic glucocorticoid dexamethasone (Dex) inhibit luminal epithelial (LE) proliferation in neonatal mouse uteri. This study determined the roles of progesterone receptor and estrogen receptor 1 (PR and ESR1, respectively) in P4-and Dex-induced inhibition of LE proliferation using PR knockout (PRKO) and Esr1 knockout (Esr1KO) mice. Wild-type (WT), heterozygous, and homozygous PRKO female pups were injected with vehicle, P4 (40 lg/g body weight), or Dex (4 or 40 lg/g body weight) on Postnatal Day 5, then 24 h later immunostained for markers of cell proliferation. In WT and heterozygous mice, P4 sharply reduced LE proliferation, and Dex produced dose-responsive decreases equaling those of P4 at the higher dose. Critically, although both doses of Dex similarly decreased proliferation compared to vehicle-treated PRKOs, treatment of PRKO pups with the high Dex dose (40 lg/g) did not inhibit LE as much as treatments of WT mice with this Dex dose or with P4. Stromal proliferation was stimulated by P4 in WT but not PRKO mice, and Dex did not alter stromal proliferation. Uteri of all genotypes strongly expressed glucocorticoid receptor (GR), demonstrating that impaired Dex effects in PRKOs did not reflect GR deficiency. Furthermore, inhibition of LE proliferation by Dex (40 lg/g body weight) in Esr1KO mice was normal, so this process does not involve ESR1. In summary, inhibitory Dex effects on LE proliferation occur partially through non-PR-mediated mechanisms, presumably GR, as indicated by Dex inhibition of LE proliferation in PRKOs. However, maximal inhibitory Dex effects on uterine LE proliferation are not seen in PRKO mice with even high Dex, indicating that maximal Dex effects in WT mice also involve PR.
INTRODUCTION
Progesterone (P4) inhibits many effects induced by 17b-estradiol (E2) in the mammalian uterus. For example, proliferation of uterine luminal epithelium (LE) induced by E2 treatment in ovariectomized mice is inhibited by concomitant treatment with P4 [1] , and rising P4 following ovulation in the normal mouse inhibits the mitogenic effects of the high levels of E2 produced in proestrous [2, 3] . Also, in neonates, P4 treatment strongly inhibits LE proliferation [4] , and this can result in permanent structural and functional alterations in the adult uterus [5] . This signature P4 effect requires nuclear progesterone receptor (PR) and is absent in PR knockout (PRKO) mice that lack both isoforms of nuclear PR [6, 7] .
Both adult [8] and neonatal [9] uteri express glucocorticoid receptor (GR) as well as PR. This suggests direct actions of glucocorticoids on uterine function and may be one mechanism by which stress and increases in endogenous glucocorticoids suppresses reproduction [10] . The synthetic glucocorticoid dexamethasone (Dex) produces an inhibition of neonatal uterine epithelial proliferation comparable in magnitude to that produced by P4 [4] , and similar inhibitory effects of Dex on E2-stimulated uterine epithelial proliferation in ovariectomized rats have been reported [11, 12] . Binding assays have shown that Dex also has some affinity for PR [9, 13] , although this binding affinity is far less than for GR. Furthermore, cross talk between glucocorticoids and PR has been demonstrated in breast cancer cells [14] . This suggests that Dex effects on uterine epithelial proliferation could be partially or even totally mediated by PR, independent of GR. Recently, it has been shown that P4 can cross-react with GR in myometrial cells [15] and uterine natural killer cells [16] to mediate anti-inflammatory actions. Furthermore, in human endometrial stromal cells, P4 treatment induced cortisol production by decidual cells, suggesting that P4 could potentially induce both progestin and glucocorticoid effects in the uterus [17] .
Glucocorticoid actions in the uterus could also involve changes in estrogen receptor 1 (ESR1) levels. Administration of Dex inhibits the E2-induced increases in ESRs in ovariectomized rats by about 80%, indicating that glucocorticoid actions may involve decreased responsiveness to estrogens as a result of decreased ESR concentrations [10] . Therefore, it has been unclear whether inhibitory effects of Dex and P4 on neonatal and adult uterine LE proliferation are mediated by effects on PR, GR, ESR1, or potentially all of these receptors. This study sought to determine the role of PR and ESR1 in Dex effects on LE and stromal proliferation in uterus using PR knockout (PRKO) mice and Esr1 knockout (Esr1KO) mice, respectively.
Our results indicate that the maximal neonatal mouse uterine LE inhibition induced by the higher Dex dose requires PR and may reflect Dex cross-reactivity with PR. In addition, non-PRmediated Dex effects, presumably through GR, also play significant roles in inhibitory Dex effects on LE proliferation, as indicated by the continued significant inhibition of LE proliferation by both low and high Dex doses in neonatal PRKO mice.
MATERIALS AND METHODS

Mice, Genotyping, and Animal Care
The Pgr knockout (PRKO) mice used in this study had a mixed C57BL/6 and 129SvEv genetic background [6] and were obtained from Drs. Francisco DeMayo and John Lydon at Baylor College of Medicine, Houston, Texas, and then subsequently bred in our colonies. These PRKO mice lack both the PR-A and -B isoforms [7] . Because homozygous PRKO females are infertile, heterozygous females were bred with either heterozygous or homozygous PRKO males to obtain wild-type (WT), heterozygous, and homozygous PRKO female pups [6, 7, 18] . Genotyping of the mice was performed by multiplex PCR on genomic DNA using PR-specific primers described previously [19] . PCR was performed by denaturing the DNA at 948C for 5 min, followed by 35 cycles of amplification (948C for 45 sec, 588C for 45 sec, 728C for 90 sec) and a final extension step at 728C for 10 min. The final PCR reaction mixture was run on 2% agarose gel with ethidium bromide to visualize PCR products.
Mice were housed in standard polycarbonate mice cages at 258C and 42% humidity with 12L:12D cycles. Mice were given water and a standard rodent diet ad libitum. All protocols and procedures were approved by the Institutional Animals Care and Use Committee of the University of Florida and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Progesterone and Dex Dosing and Tissue Collection in Neonatal Mouse Pups
Our previous work indicated that one dose of P4 at 40 lg/g body weight (BW) maximally inhibited uterine epithelial proliferation in neonatal mice [4, 5] , and thus this dose was utilized in the present studies. Progesterone (P9372; Sigma-Aldrich) was dissolved in filter-sterilized peanut oil (P2144; SigmaAldrich), and the 40 lg/g BW dose was injected in 50 ll of oil at Postnatal Day 5 (birth ¼ Day 0). Dexamethasone (16505; APP Pharmaceuticals) was injected subcutaneously at 4 and 40 lg/g BW in 50 ll. For control pups, 50 ll of peanut oil was injected subcutaneously. All the females in a litter were given the same treatment (P4, Dex, or vehicle) to avoid misidentification and/or crosscontamination. Pups from at least two to three different litters were used for each treatment group. At 24 h after injections (Postnatal Day 6), all the female pups from the litter were decapitated, and uterine horns and tail tip were collected in 10% neutral formalin and genomic DNA extraction solution (XNAT; Sigma-Aldrich), respectively. Uteri were fixed for 48 h, then processed for histology and immunohistochemistry, while tail tips were processed for genomic DNA isolation according to manufacturer's instructions. Genotypes were determined retrospectively as described above.
The ability of Dex to inhibit E2-induced uterine epithelial proliferation in the adult is a hallmark of Dex effects [11] . A previous study suggests E2-antagonizing effects of Dex in the uterus are partially mediated by decreasing uterine ESRs [10] . To determine whether Dex effects on neonatal uterine LE proliferation involve or require the main estrogen receptor (ESR1), the effects of Dex (40 lg/g BW) or oil vehicle on 5-day-old WT and Esr1KO mice, bred and genotyped as described previously [20] , were also examined.
Expression of PR and GR in Neonatal Mouse Uterus
Localization of PR and GR in neonatal uteri was determined using immunohistochemistry (IHC), while immunoblotting was used to determine expression levels of these proteins. The IHC was performed as described previously [21] . Paraffin sections of neonatal uteri were immunostained with rabbit immunoglobulin G (IgG) raised against human PR (1:4000; A0098; Dako) and GR (1:2000; 12041; Cell Signaling Technologies). Uteri from vehicle-treated WT, heterozygous, and PRKO pups were stained. In addition, uteri from neonatal mice given one injection of P4 or Dex as described above were also immunostained for PR (WT) and GR (WT and PRKO). For immunoblot analysis, three to five uteri (Day 6) from oil-treated WT, heterozygous, and PRKO pups from different litters were dissolved in lysis buffer, and total protein concentrations were determined. Equal amounts of protein from the WT, heterozygous, and PRKO groups were resolved in 6% SDS PAGE and blotted onto nitrocellulose membrane by applying electric current. Subsequently, membranes were blocked with 5% nonfat milk in 10 mM Tris, 150 mM NaCl, and 0.05% Tween 20 (TBST) followed by overnight incubation with primary antibodies against PR (1:2000) and GR (1:2000) in 5% milk TBST. The following day, membranes were washed in TBST and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (BioRad Laboratories) for 1 h, then washed in TBST before exposure to chemiluminescence reagents and x-ray film. Actin concentrations were used as loading controls.
Assessment of Uterine Cell Proliferation
To assess uterine cell proliferation, uteri from pups injected with peanut oil, P4, or Dex were fixed, paraffin embedded, sectioned at 5-6 lm, and immunostained for MKI67 or phospho-histone H3 Serine 10 (PHH3 Ser10 ), markers of cell proliferation, using a rabbit monoclonal IgG to human-MKI67 (ab16667; Abcam, Inc.) or the rabbit polyclonal IgG to phosphorylated Ser10 of human histone H3 (9701; Cell Signaling Technologies), respectively, following antigen retrieval as described previously [21] . Negative controls for both proteins were processed without primary antibody. Following immunostaining, tissues were counterstained with Gills hematoxylin (245-654; Fisher Scientific).
Determination of Labeling Indices and Statistical Analyses
Uterine epithelial or stromal cell labeling index (i.e., number of cells labeled/total counted 3 100) was determined by quantitating MKI67 or PHH3 Ser10 -positive cells in ;500 epithelial or stromal cells from at least two sections of each uterine horn sampled 60 to 120 lm apart from WT, heterozygous, and PRKO mice given vehicle, P4, or Dex at Postnatal Day 5. A similar protocol was used to assess Dex effects on uterine epithelial and stromal cell proliferation in neonatal WT, heterozygous, and Esr1KO mice. One to two pups from at least two to three different litters for each hormone or vehicle treatment groups were used. Microscopic images for all groups were captured and then displayed on a computer screen and counted manually. All the data presented in a particular figure were scored blind by the same observer. Data were analyzed using two-way ANOVA followed by Tukey multiple comparison tests to identify effects of P4 and Dex among the individual genotypes and presented as mean 6 SEM. Differences were considered significant at P , 0.05. Statistical analysis was carried out using Graph Pad Prism 6.0 (Graph Pad Software, Inc.).
RESULTS
Expression of PR and GR in Neonatal Uterus
We examined PR expression by IHC in neonatal uteri of all three genotypes (PR
, and PR À/À ) treated with oil vehicle, P4, or Dex, and also examined PR expression by Western blot analysis in oil-treated controls of all three
, and PR
À/À
). Expression of PR in oil-treated WT uteri was pronounced in LE and minimal in stroma (Fig. 1A) . In heterozygotes, a similar pattern of expression was seen, although overall intensity of epithelial PR expression was reduced compared to WT controls. In oiltreated PRKO mice, PR immunostaining was not observed. Treatment with P4 produced clear decreases in epithelial PR expression in WT mice, while Dex modestly decreased epithelial PR expression (Supplemental Fig. S1 ; available online at www.biolreprod.org).
Strong expression of GR was observed in uterine stroma from oil-treated WT, heterozygous, and PRKO neonates (Fig.  1B) . Epithelial staining for GR was less than the stroma and heterogeneous, with some LE in all groups showing strong staining, while other cells showed minimal staining. Treatment of WT mice with Dex (40 lg/g BW) modestly decreased uterine GR (Supplemental Fig. S1 ), while P4 (40 lg/g BW) had no clear effect. Neither P4 nor Dex produced obvious changes in GR expression in PRKO uteri (Supplemental Fig.  S1 ).
Immunoblots of uteri from oil-treated WT pups for PR indicated that both the 115 kDa PR-B and 83 kDa PR-A isoforms of PR were strongly expressed (Fig. 1D) . Consistent with IHC results, PR expression was reduced in heterozygous uteri, and neither PR isoform was detected in PRKO uteri. Immunoblotting for GR in uteri of oil-treated WT, heterozygous, and PRKO pups (Fig. 1C) indicated that the GR of the NANJAPPA ET AL. expected 97 kDa size was present in all three groups and did not vary with genotype, indicating that PR deletion does not alter uterine GR expression.
Effects of P4 and Dex on Cell Proliferation in Neonatal Uteri
One P4 injection (40 lg/g BW) in neonatal WT and heterozygous mice sharply decreased uterine LE proliferation compared to oil-treated WT controls when assessed by either MKI67 (Figs. 2 and 3 ) or PHH3 Ser10 immunostaining (Fig. 4 , A and B). Treatment with Dex produced a dose-responsive suppression in LE proliferation in both WT and heterozygous mice, although the magnitude of the decreases detected in response to P4 or Dex were more pronounced with PHH3 Ser10 than with MKI67 (Figs. 2-4) . The higher Dex dose (40 lg/g BW) suppressed uterine LE proliferation in WT neonatal mice to a similar degree as P4 when assessed by either MKI67 (Figs. 2 and 3) or PHH3 Ser10 (Fig. 4) . Proliferation of LE in PRKO mice given vehicle was high and comparable to vehicle-treated WT and heterozygous mice when assessed either by MKI67 or PHH3 Ser10 (Figs. 2-4) . In striking contrast to results obtained in WT and heterozygous mice, administration of P4 to PRKO mice produced a small decrease that did not reach statistical significance in LE proliferation assessed by MKI67 (Fig. 3 ) and a significant 15% decrease (P ¼ 0.03) when assessed by PHH3 Ser10 (Fig. 4) . Critically, both 4 and 40 lg/g BW Dex treatments of PRKO pups produced significant and comparable decreases in LE proliferation compared to vehicle-treated PRKO controls (Figs. 2-4 ). The decreases induced by both Dex doses in PRKO pups were more pronounced when assessed by PHH3 Ser10 than by MKI67. Importantly, the 40 lg/ g BW Dex treatment of PRKO pups resulted in a greater than 50% suppression of LE compared to vehicle-treated PRKO controls when proliferation was assessed by PHH3 Ser10 , indicating that non-PR-mediated effects could cause clear suppression of LE. However, even the high Dex dose did not cause as pronounced of a decrease in the labeling index as with this treatment in WT mice when assessed by either PHH3 Ser10 (P ¼ 0.004) or MKI67 (P , 0.001), indicating that full Dex inhibition of LE proliferation at 40 lg/g BW was not obtained in PRKO mice lacking PR (Figs. 3 and 4) .
Proliferation of stromal cells in neonatal WT and heterozygous uteri given P4 showed a modest stimulation (Figs. 2 and  3 ), but stromal proliferation was unaffected or slightly reduced by Dex. In contrast, neither P4 nor Dex altered stromal cell 
) mice by immunohistochemistry and Western blot analysis (D). A)
Immunostaining for PR revealed that luminal epithelial (LE) expression was high, although some stromal (S) staining was also seen. Expression of PR was reduced in heterozygotes compared to WT and was not seen in PRKO uteri. B) Immunostaining for GR was pronounced in stromal cells and lighter and more heterogeneous in epithelial cells. Staining for GR did not vary among the genotypes. C) Control for nonspecific staining with the secondary goat anti-rabbit biotinylated IgG. This section was stained for PR or GR as described above, but the primary antibody was omitted. D) Western blot analysis indicated two bands corresponding to PR-B (115 kDa) and PR-A (83 kDa) at the expected sizes. The intensity of both PR-B and PR-A bands were reduced in uteri of heterozygous mice compared to WT controls, and PR expression was not detected in PRKO mice. One band representing GR was observed at the expected 97 kDa size. Consistent with immunohistochemical results in B, GR expression was comparable in uteri from various genotypes. Actin was used as a loading control for Western blot analysis and is shown beneath the PR and GR panels. Four to five mice were used for all groups that were derived from two to three separate litters. The entire experiment was repeated twice, and each result was comparable. All the images are at the same magnification, and the bar ¼ 50 lm.
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proliferation in PRKO mice compared to oil vehicle-treated PRKO mice (Figs. 2 and 3) .
Treatment with one Dex injection (40 lg/g BW) in neonatal WT, heterozygous, and Esr1KO mice sharply decreased uterine epithelial proliferation compared to the high proliferation seen in all genotypes treated with peanut oil (P , 0.0001, Fig. 5 ). However, stromal proliferation was unaffected by Dex treatment. Thus, the inhibitory effects of Dex do not involve and are not dependent on ESR1.
DISCUSSION
The synthetic glucocorticoid Dex produces an inhibition of uterine LE proliferation in neonatal mice that is similar in magnitude to that obtained with P4 [4] . Treatment with Dex also antagonizes the E2-induced stimulation of epithelial secretory proteins such as complement component C3 [22] and inhibits many proinflammatory E2 effects in the uterus [23] . More recent array studies have shown that glucocorticoids such as Dex produce a large number of effects on gene expression in both uterine epithelium and stroma as well as in uterine cell lines [17, [24] [25] [26] .
Glucocorticoid effects could be mediated through GR, as demonstrated by expression of GR in neonatal and adult uteri [8, 9] and knockdown of GR by small interfering RNA in human endometrial stromal cells, which led to the identification of over 200 genes that were regulated by GR in these cells [17] . However, binding of Dex and other glucocorticoids to PR has been demonstrated [9, 13] , although affinity of these compounds for PR is far less than that of P4. In addition, glucocorticoid cross talk with PR to produce P4-like effects in a breast cancer cell line has been reported [14] , suggesting that glucocorticoid signaling through PR can produce biologically significant changes. Thus, it has been unclear whether Dex modulates LE proliferation by acting through PR, GR, or potentially both.
Preliminary results using agonists and antagonists of PR and GR were consistent with the idea that P4 (40 lg/g BW) acted through PR and Dex (1 lg/g BW) acted through GR to inhibit LE proliferation [9] . However, definitive interpretation of these experiments is problematical because antagonists of PR or GR typically have affinity for the other receptors [27] .
Development of PRKO mice in which both forms of the classical nuclear receptor are deleted [6, 7] has facilitated However, the magnitude of inhibitory 40 lg/g BW P4 and Dex effects in heterozygous (Het) pups was reduced compared to WT. In contrast, LE proliferation in PR knockout (PRKO) pups was not as dramatically decreased as in WT and Het following P4 or Dex. Compared to vehicletreated WT and Het, stromal (S) proliferation was modestly increased by P4 but not by Dex. However, P4-stimulated stromal proliferation was absent in PRKO pups. All the images are at the same magnification; bar ¼ 50 lm. The number of mice are as follows: WT mice given vehicle, P4, or Dex at 4 and 40 lg/g BW (n ¼ 5-6, 4, and 7, respectively); Het given vehicle, P4, or Dex at 4 and 40 lg/g BW (n ¼ 4, 6, 4, and 5, respectively); and PRKO mice given vehicle, P4 or Dex at 4 and 40 lg/g BW (n ¼ 11, 9, 4, and 5, respectively).
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understanding of the roles of these receptors in both reproductive and nonreproductive tissue. These animals allow the determination of the mechanism of Dex effects on uterine epithelial proliferation by studying the effects in the total absence of a particular receptor, avoiding problems associated with pharmacological inhibitors of these receptors and their cross-reactivity. In this study, we utilized PRKO mice to experimentally determine the role of PR in Dex effects on neonatal uterine LE proliferation.
Both Dex and P4 produce sharp inhibitions in LE proliferation in WT mice, consistent with previous work [4, 9] . The Dex inhibition of LE proliferation in WT and heterozygous mice shows dose-responsive effects, with the lower 4 lg/g BW Dex dose producing over a 60% decrease in LE proliferation when assessed by PHH3 Ser10 expression. These results are consistent with previous literature showing that Dex effects were dose-responsive and that doses as low as 0.6 and 1.0 lg/g BW reduced neonatal rodent uterine LE proliferation more than 50% [9, 22] .
The 40 lg/g BW Dex dose used in this study was selected based on the original report of Dex inhibition of LE proliferation [4] . The ability of the 4 lg/g BW Dex dose used here to significantly suppress LE proliferation and earlier reports that doses as low as 0.6 lg/g BW, which are comparable to those used in some human pediatric medical conditions [28, 29] , inhibited neonatal rodent uterine LE proliferation [9, 22] suggests that Dex doses used in human medicine may alter uterine epithelial proliferation. This emphasizes the clinical relevance of understanding the mechanism of Dex actions on uterine epithelial proliferation.
Our results indicate that maximally inhibitory effects of 40 lg/g BW doses of Dex and P4 on LE proliferation are not seen in PRKO neonates and thus PR is required. These findings are consistent with extensive previous work in PRKO mice showing the absence of many classic P4 effects in these animals [6, 7] . Preliminary results suggest that our observation that PR is required for full Dex inhibition of neonatal uterine LE proliferation also holds true in adults (Bigsby, unpublished data) . Previous literature has documented Dex affinity for PR [9, 13] , and glucocorticoid cross talk through PR is documented [14] . Therefore, Dex may be able to inhibit epithelial proliferation through PR binding and initiation of downstream events similar to those induced by P4. However, other modes of Dex action cannot be ruled out a priori [30] . were also seen in Het mice, although this was less pronounced than in WT. In PRKO mice, the large decreases produced by P4 and Dex in WT mice were not seen, although Dex at either 4 and 40 lg/g BW produced significant decreases in epithelial labeling. Stromal proliferation in WT and Het mice, but not PRKO mice, was increased by P4. Treatment with Dex either had no effect or a mild suppressive effect on stromal cell proliferation. Data are expressed in mean 6 SEM. Bars with a different superscript within each genotype are different at P 0.05. The number of mice for WT, Het, and PRKO mice given vehicle, P4, or 40 lg/g Dex were as indicated in the legends for Figures 2 and 3 , and n ¼ 3 for the 4 lg/g BW Dex dose in each of the WT, Het, and PRKO groups.
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Despite the absence of PR precluding the full inhibitory response of neonatal LE to P4 or the 40 lg/g BW Dex dose, significant decreases in LE proliferation was still seen in PRKO mice following 4 and 40 lg/g BW Dex treatment. The magnitude of the decrease seen with this Dex dose in PRKO mice was .50% when assessed by PHH3 Ser10 , although less (;15%) when assessed by MKI67. These Dex effects in PRKO mice suggest that Dex and other glucocorticoids can have significant effects on epithelial proliferation that are independent of PR, and these most likely occur through Dex binding to GR. The similar inhibition of LE proliferation by the low and high Dex doses in PRKO mice indicates that the threshold concentration of Dex needed for a maximal response is relatively low, which would be consistent with Dex effects on LE in PRKO mice occurring through GR. In addition, the ability of the low Dex dose to produce comparable LE decreases in WT, heterozygous, and PRKO mice when assessed by either MKI67 or PHH3 Ser10 suggests that Dex effects at lower doses might be preferentially through a non-PR-mediated mechanism, while significantly greater effects NANJAPPA ET AL. through PR might be seen at the higher (40 lg/g BW) Dex dose. This would be consistent with the high affinity of Dex for its cognate receptor, GR, and its much lower affinity for PR. Thus, although maximally inhibitory effects of Dex on LE proliferation require PR, there are also non-PR-mediated effects, potentially through GR, which appear to also play an important role in inhibitory Dex effects on LE proliferation.
MKI67 protein is expressed in all phases of the cell cycle but not during G0. During the G1 and S phase, MKI67 is present, but it begins to rise toward the end of G2, peaking at mitosis then declining sharply at the end of the mitosis [31] . Therefore, MKI67 is a marker for the entire proliferative fraction of a cell population and is expressed across the cell cycle [31] . Phosphorylation of histone H3 at Serine 10 is associated with chromatin condensation during mitosis [32] . Hyperphosphorylation of histone H3 at Serine 10 begins toward the end of G2 phase and becomes maximal during the mitosis (M) phase of the cycle [32] . Therefore, PHH3
Ser10 is a more specific marker of the M-phase [33] , which accounts for the much lower percentage of cells that are positive for PHH3 Ser10 compared to MKI67 in vehicle-treated WT mice. Previous work using a variety of uterine and other cell types has demonstrated that Dex and P4 inhibit proliferation in the late G1 phase of the cycle [34] [35] [36] . The sharp decline in LE proliferation in response to P4 or Dex assessed by PHH3 Ser10 expression contrasts with the significant but clearly less robust decrease in LE proliferation when assessed by MKI67 immunostaining. This is likely a result of the P4 and Dex effects on LE in blocking proliferation in late G1, which will strongly reduce the number of cells in M-phase, as assessed by PHH3 Ser10 expression. Conversely, the production of MKI67 in the LE across the cell cycle will result in a proportionately smaller decrease in its expression compared to PHH3
Ser10 if the cell cycle is blocked at late G1, as has been observed 
previously with other cell types [37] ; PHH3 Ser10 may therefore have advantages over-MKI67 when assessing treatments that alter cell proliferation in the uterus.
Interestingly, P4 administration to PRKO mice may have a minor inhibitory effect on LE proliferation, although effects detected by PHH3 Ser10 were modest and those obtained with MKI67 did not reach statistical significance. Thus, P4 in PRKO mice could have a small inhibitory effect on LE proliferation by acting through some mechanism independent of PR. Progesterone has significant affinity for GR [9, 13] , and residual P4 effects in PRKO mice could be due to P4 signaling through GR, although other mechanisms cannot be excluded.
Uterine expression of GR has been shown to be regulated by P4/PR signaling [17] , raising the possibility that the lack of PR in PRKO mice could alter uterine GR expression or distribution, and potentially impair Dex responses in this manner. Our Western blot results show that WT and PRKO uteri express equal levels of GR. Furthermore, immunohistochemistry results indicate that the typical cellular distribution seen in WT mice, intense GR expression in stroma and less intense and more heterogeneous epithelial GR expression, is not altered in PRKO mice. Thus, the inability of Dex to produce the magnitude of decreases in LE proliferation in PRKO mice that it does in WT mice is not a result of lack of GR, and instead reflects the fact that PR is necessary to allow the maximal inhibitory effect of 40 lg/g BW Dex on uterine LE.
Previous work indicated that neonatal uterine stromal proliferation is stimulated by P4 [4] . Conversely, despite its ability to produce inhibition of epithelial proliferation similar to that observed with P4, Dex does not stimulate stromal proliferation [4] . Our results confirm those earlier findings and also demonstrate that mitogenic effects of P4 on neonatal uterine stromal cells are lost in PRKO mice.
In adult mice, inhibition of proliferative responses to E2 or other estrogens by Dex [11, 12] suggests that inhibitory Dex effects on uterine LE could involve ESR1, which mediates these mitogenic effects, or at least be dependent on the presence of ESR1 for antimitogenic effects. Furthermore, coadministration of Dex and E2 inhibits E2-induced increases in uterine ESRs [10] , suggesting that Dex actions may involve decreased ESR1 and mitogenic responsiveness to E2. The normal Dex inhibition of uterine epithelial proliferation in neonatal Esr1KO mice indicates that Dex effects are not dependent on or involve ESR1 and must occur downstream of the E2/ESR1 interaction. These findings are consistent with P4 inhibition of neonatal uterine epithelial proliferation also being independent of ESR1, as recently reported by our group [38] and others [39, 40] .
In summary, our results indicate that the maximal inhibitory effect of Dex on neonatal uterine epithelial proliferation requires PR. Despite the importance of PR for mediating Dex effects, our results indicate that non-PR-mediated pathways (possibly through GR) may also be involved in inhibitory effects of both Dex on neonatal uterine epithelial proliferation.
